These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 3052008)

  • 21. Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
    Rae AP; Spielman SR; Kutalek SP; Kay HR; Horowitz LN
    Am J Cardiol; 1987 Feb; 59(4):291-5. PubMed ID: 3544793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac electrophysiologic testing: its role in the selection of antiarrhythmic drug regimens for supraventricular and ventricular arrhythmias.
    Cameron J; Isner JM; Salem DM; Estes NA
    Pharmacotherapy; 1985; 5(2):95-107. PubMed ID: 3889871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease.
    Kudenchuk PJ; Kron J; Walance CG; Cutler JE; Griffith KK; McAnulty JH
    Am J Cardiol; 1990 Sep; 66(7):725-30. PubMed ID: 2399890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of programmed electrical stimulation and ambulatory electrocardiographic (Holter) monitoring in the management of ventricular tachycardia and ventricular fibrillation.
    Platia EV; Reid PR
    J Am Coll Cardiol; 1984 Sep; 4(3):493-500. PubMed ID: 6470328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.
    Reiffel JA
    Am J Cardiol; 1996 Aug; 78(4A):34-40. PubMed ID: 8780327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ESVEM trial. Electrophysiologic Study Versus Electrocardiographic Monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. The ESVEM Investigators.
    Circulation; 1989 Jun; 79(6):1354-60. PubMed ID: 2655967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electropharmacology of nonsustained ventricular tachycardia: effects of class I antiarrhythmic agents, verapamil and propranolol.
    Buxton AE; Waxman HL; Marchlinski FE; Josephson ME
    Am J Cardiol; 1984 Mar; 53(6):738-44. PubMed ID: 6702622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Are anti-arrhythmia agents superior to a beta blocker in treating life-threatening ventricular arrhythmias? Preliminary results of a controlled study].
    Steinbeck G; Andresen D; von Leitner ER
    Z Kardiol; 1986; 75 Suppl 5():47-55. PubMed ID: 2435071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiologic approach to therapy of recurrent sustained ventricular tachycardia.
    Josephson ME; Horowitz LN
    Am J Cardiol; 1979 Mar; 43(3):631-42. PubMed ID: 369349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Philadelphia Arrhythmia Group.
    Kowey PR; Waxman HL; Greenspon A; Greenberg R; Poll D; Kutalek S; Gessman L; Muenz L
    Am J Cardiol; 1990 Mar; 65(9):594-8. PubMed ID: 2309629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome in patients who survive out of hospital ventricular fibrillation and undergo electrophysiologic studies: evaluation by electrophysiologic subgroups.
    Poole JE; Mathisen TL; Kudenchuk PJ; McAnulty JH; Swerdlow CD; Bardy GH; Greene HL
    J Am Coll Cardiol; 1990 Sep; 16(3):657-65. PubMed ID: 2387939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
    Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
    Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and electrophysiologic findings in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram.
    Rahilly GT; Prystowsky EN; Zipes DP; Naccarelli GV; Jackman WM; Heger JJ
    Am J Cardiol; 1982 Sep; 50(3):459-68. PubMed ID: 6810685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
    Buxton AE; Lee KL; Fisher JD; Josephson ME; Prystowsky EN; Hafley G
    N Engl J Med; 1999 Dec; 341(25):1882-90. PubMed ID: 10601507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation.
    Kim SG; Felder SD; Waspe LE; Fisher JD
    Am J Cardiol; 1986 Sep; 58(6):485-90. PubMed ID: 3529910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is programmed stimulation of value in predicting the long-term success of antiarrhythmic therapy for ventricular tachycardias?
    Kim SG; Seiden SW; Felder SD; Waspe LE; Fisher JD
    N Engl J Med; 1986 Aug; 315(6):356-62. PubMed ID: 2426592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amiloride. Antiarrhythmic and electrophysiologic actions in patients with inducible sustained ventricular tachycardia.
    Duff HJ; Mitchell LB; Kavanagh KM; Manyari DE; Gillis AM; Wyse DG
    Circulation; 1989 Jun; 79(6):1257-63. PubMed ID: 2720927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Which patient with sustained ventricular tachycardia is suited for long-term therapy with anti-arrhythmia drugs?].
    Steinbeck G
    Z Gesamte Inn Med; 1992 May; 47(5):195-201. PubMed ID: 1615729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study.
    Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN
    Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic drug exacerbation of ventricular tachycardia inducibility during electrophysiologic study.
    Sager PT; Perlmutter RA; Rosenfeld LE; Batsford WP
    Am Heart J; 1992 Apr; 123(4 Pt 1):926-33. PubMed ID: 1550002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.